Nanostructured Drug Delivery Systems for Targeting 5-Alpha-Reductase Inhibitors to the Hair Follicle

    January 2022 in “ Pharmaceutics ”
    Silvia Tampucci, Valentina Paganini, Susi Burgalassi, Patrizia Chetoni, Daniela Monti
    Image of study
    TLDR Nanostructured delivery systems could potentially improve hair loss treatment by targeting drugs to hair follicles, reducing side effects and dosage, but the best size, charge, and materials for these systems need further investigation.
    The document reviews the development of nanostructured drug delivery systems for targeting 5-α-reductase inhibitors to the hair follicle, a potential treatment for androgenetic alopecia. Current treatments like minoxidil and finasteride have side effects and require repeated applications. The new strategies aim to improve drug retention in the hair follicle, reducing systemic absorption and side effects. The research focuses on factors like particle size, surface charge, and excipients. The document also mentions dutasteride, a promising drug for alopecia treatment. The document concludes that nanostructured delivery systems could improve drug distribution in the hair follicle region, reduce side effects, and lower the required dose. However, the optimal size, surface charge, and combination of polymers and/or surfactants for the nanoparticles should be investigated to maximize their effectiveness.
    Discuss this study in the Community →

    Research cited in this study

    45 / 45 results

    Related Community Posts Join

    6 / 1000+ results

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  42 upvotes 5 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 4 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    10 / 10 results